This complements the PD-1+CD8+ T cell findings: together, they paint a clear immune landscape—residual tumor risk is elevated in patients with an “exhausted” immune profile (high PD-1+CD8+ T cells) and reduced in those with an “activated” profile (high CD28+CD4+ T cells). Here, CD28 is linked to neoplasm.